Pfenex Lands $24,000,000 New Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=86113017-895b-43bd-8be4-fb33b4b30c85&Preview=1 -
Date
12/10/2009 -
Company Name
Pfenex -
Mailing Address
5501 Oberlin Drive San Diego, CA 92121 -
Company Description
Headquartered in San Diego, California, Pfenex Inc. is a leading biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars. The Company’s core technology, Pfenex Expression Technology™, is a cutting edge protein expression platform that utilizes the BSL-1 microorganism Pseudomonas fluorescens. Pfenex Expression Technology™ combines an extensive toolbox of expression components with a robotically enabled high throughput parallel strain screening technology, delivering unprecedented speed and success in identifying protein production strains expressing high titers of soluble active protein. -
Website
http://www.pfenex.com -
Transaction Type
Venture Equity -
Transaction Amount
$24,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Proceeds purposes were not disclosed. -
M&A Terms
-
Venture Investor
Dow Venture Capital -
Venture Investor
Signet Healthcare Partners
